FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) has received a Staff Deficiency Letter from The Nasdaq Stock Market notifying GTC that for the last 10 consecutive trading days the aggregate market value of GTCB common stock has fallen below $50 million, the minimum level required for continued listing on the Nasdaq Global Market, as specified by the Marketplace Rule 4450(b)(1)(A). This notice initiates the timetable for review of GTC’s continued inclusion on the Nasdaq Global Market, but it has no immediate effect on the listing of GTCB on that market.
